Skip to Content

Generic Iluvien Availability

Iluvien is a brand name of fluocinolone ophthalmic, approved by the FDA in the following formulation(s):

ILUVIEN (fluocinolone acetonide - implant;intravitreal)

  • Manufacturer: ALIMERA SCIENCES INC
    Approval date: September 26, 2014
    Strength(s): 0.19MG [RLD]

Has a generic version of Iluvien been approved?

No. There is currently no therapeutically equivalent version of Iluvien available in the United States.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Iluvien. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Method for treating and/or preventing retinal diseases with sustained release corticosteroids
    Patent 6,217,895
    Issued: April 17, 2001
    Inventor(s): Guo; Hong & Ashton; Paul
    Assignee(s): Control Delivery Systems
    The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
    Patent expiration dates:
    • March 22, 2019
      ✓ 
      Patent use: TREATMENT OF DIABETIC MACULAR EDEMA
      ✓ 
      Drug product
  • Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
    Patent 6,375,972
    Issued: April 23, 2002
    Inventor(s): Hong; Guo & Paul; Ashton
    Assignee(s): Control Delivery Systems, Inc.
    A method and device for treating a mammalian organism to obtain a desired local or systemic physiological or pharmacological effect is provided. The method includes administering a sustained release drug delivery system to a mammalian organism in need of such treatment at an area wherein release of an effective agent is desired and allowing the effective agent to pass through the device in a controlled manner. The device includes an inner core or reservoir including the effective agent, an impermeable tube which encloses portions of the reservoir, and a permeable member at an end of the tube.
    Patent expiration dates:
    • April 26, 2020
      ✓ 
      Patent use: TREATMENT OF DIABETIC MACULAR EDEMA
      ✓ 
      Drug product
  • Method for treating and/or preventing retinal diseases with sustained release corticosteroids
    Patent 6,548,078
    Issued: April 15, 2003
    Inventor(s): Hong; Guo & Paul; Ashton
    Assignee(s): Control Delivery Systems
    The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
    Patent expiration dates:
    • March 22, 2019
      ✓ 
      Patent use: TREATMENT OF DIABETIC MACULAR EDEMA
      ✓ 
      Drug product
  • Method for treating and/or preventing retinal diseases with sustained release corticosteroids
    Patent 8,252,307
    Issued: August 28, 2012
    Inventor(s): Ashton; Paul
    Assignee(s): pSivida US, Inc.
    The present invention relates to a method for administering a corticosteroid to a posterior segment of an eye. In the method, a sustained release device is implanted to deliver the corticosteroid to the eye. The aqueous corticosteroid concentration remains less than vitreous corticosteroid concentration during release of the corticosteroid from the device.
    Patent expiration dates:
    • June 27, 2019
      ✓ 
      Drug product
  • Injectable sustained release delivery devices
    Patent 8,871,241
    Issued: October 28, 2014
    Assignee(s): pSivida US, Inc.
    An injectable drug delivery device includes a core containing one or more drugs and one or more polymers. The core may be surrounded by one or more polymer outer layers (referred to herein as “coatings,” “skins,” or “outer layers”). In certain embodiments, the device is formed by extruding or otherwise preforming a polymeric skin for a drug core. The drug core may be co-extruded with the skin, or inserted into the skin after the skin has been extruded, and possibly cured. In other embodiments, the drug core may be coated with one or more polymer coatings. These techniques may be usefully applied to fabricate devices having a wide array of drug formulations and skins that can be selected to control the release rate profile and various other properties of the drugs in the drug core in a form suitable for injection using standard or non-standard gauge needles. The device may be formed by combining at least one polymer, at least one drug, and at least one liquid solvent to form a liquid suspension or solution wherein, upon injection, such suspension or solution under goes a phase change and forms a gel. The configuration may provide for controlled release of the drug(s) for an extended period.
    Patent expiration dates:
    • August 12, 2027
      ✓ 
      Drug product

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:
    • September 26, 2017 - NEW PRODUCT

Glossary

TermDefinition
Drug PatentA drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug ExclusivityExclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLDA Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
Hide